In vitro activity of ceftazidime-avibactam against carbapenem-resistant and hypervirulent klebsiella pneumoniae isolates

Fangyou Yu; Jingnan Lv; Siqiang Niu; Hong Du; Yi Wei Tang; Robert A. Bonomo; Barry N. Kreiswirth; Liang Chen

doi:10.1128/AAC.01031-18

In vitro activity of ceftazidime-avibactam against carbapenem-resistant and hypervirulent klebsiella pneumoniae isolates

Fangyou Yu
, Jingnan Lv
, Siqiang Niu
, Hong Du
, Yi Wei Tang
, Robert A. Bonomo
, Barry N. Kreiswirth
, Liang Chen

Tongji University
First Affiliated Hospital of Wenzhou Medical University
First Affiliated Hospital of Chongqing Medical University
Second Affiliated Hospital of Soochow University
Memorial Sloan-Kettering Cancer Center
Cornell University
Case Western Reserve University
Louis Stokes Cleveland Department of Veterans Affairs Medical Center
Public Health Research Institute, New York

Research output: Contribution to journal › Article › peer-review

32 Scopus citations

Abstract

Carbapenem-resistant and hypervirulent Klebsiella pneumoniae (CR-hvKp) strains have emerged while antimicrobial treatment options remain limited. Herein, we tested the in vitro activity of ceftazidime-avibactam and other comparator antibiotics against 65 CR-hvKp isolates. Ceftazidime-avibactam, colistin, and tigecycline are highly active in vitro against CR-hvKp isolates (MIC₉₀, 1 g/ml), including K. pneumoniae carbapenemase 2 (KPC-2)-producing ST11 CR-hvKp. On the basis of previous clinical experience and the in vitro data presented herein, we posit that ceftazidime-avibactam is a therapeutic option against CR-hvKp infections.

Original language	English
Article number	e01031-18
Journal	Antimicrobial Agents and Chemotherapy
Volume	62
Issue number	8
DOIs	https://doi.org/10.1128/AAC.01031-18
State	Published - Aug 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Carbapenem resistance
Ceftazidime-avibactam
Hypervirulent Klebsiella pneumoniae
Susceptibility

Access to Document

10.1128/AAC.01031-18

Cite this

@article{77362436393f4eefb2a18d173d386437,

title = "In vitro activity of ceftazidime-avibactam against carbapenem-resistant and hypervirulent klebsiella pneumoniae isolates",

abstract = "Carbapenem-resistant and hypervirulent Klebsiella pneumoniae (CR-hvKp) strains have emerged while antimicrobial treatment options remain limited. Herein, we tested the in vitro activity of ceftazidime-avibactam and other comparator antibiotics against 65 CR-hvKp isolates. Ceftazidime-avibactam, colistin, and tigecycline are highly active in vitro against CR-hvKp isolates (MIC90, 1 g/ml), including K. pneumoniae carbapenemase 2 (KPC-2)-producing ST11 CR-hvKp. On the basis of previous clinical experience and the in vitro data presented herein, we posit that ceftazidime-avibactam is a therapeutic option against CR-hvKp infections.",

keywords = "Carbapenem resistance, Ceftazidime-avibactam, Hypervirulent Klebsiella pneumoniae, Susceptibility",

author = "Fangyou Yu and Jingnan Lv and Siqiang Niu and Hong Du and Tang, \{Yi Wei\} and Bonomo, \{Robert A.\} and Kreiswirth, \{Barry N.\} and Liang Chen",

year = "2018",

month = aug,

doi = "10.1128/AAC.01031-18",

language = "English",

volume = "62",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "8",

}

TY - JOUR

T1 - In vitro activity of ceftazidime-avibactam against carbapenem-resistant and hypervirulent klebsiella pneumoniae isolates

AU - Yu, Fangyou

AU - Lv, Jingnan

AU - Niu, Siqiang

AU - Du, Hong

AU - Tang, Yi Wei

AU - Bonomo, Robert A.

AU - Kreiswirth, Barry N.

AU - Chen, Liang

PY - 2018/8

Y1 - 2018/8

N2 - Carbapenem-resistant and hypervirulent Klebsiella pneumoniae (CR-hvKp) strains have emerged while antimicrobial treatment options remain limited. Herein, we tested the in vitro activity of ceftazidime-avibactam and other comparator antibiotics against 65 CR-hvKp isolates. Ceftazidime-avibactam, colistin, and tigecycline are highly active in vitro against CR-hvKp isolates (MIC90, 1 g/ml), including K. pneumoniae carbapenemase 2 (KPC-2)-producing ST11 CR-hvKp. On the basis of previous clinical experience and the in vitro data presented herein, we posit that ceftazidime-avibactam is a therapeutic option against CR-hvKp infections.

AB - Carbapenem-resistant and hypervirulent Klebsiella pneumoniae (CR-hvKp) strains have emerged while antimicrobial treatment options remain limited. Herein, we tested the in vitro activity of ceftazidime-avibactam and other comparator antibiotics against 65 CR-hvKp isolates. Ceftazidime-avibactam, colistin, and tigecycline are highly active in vitro against CR-hvKp isolates (MIC90, 1 g/ml), including K. pneumoniae carbapenemase 2 (KPC-2)-producing ST11 CR-hvKp. On the basis of previous clinical experience and the in vitro data presented herein, we posit that ceftazidime-avibactam is a therapeutic option against CR-hvKp infections.

KW - Carbapenem resistance

KW - Ceftazidime-avibactam

KW - Hypervirulent Klebsiella pneumoniae

KW - Susceptibility

UR - https://www.scopus.com/pages/publications/85052024457

U2 - 10.1128/AAC.01031-18

DO - 10.1128/AAC.01031-18

M3 - Article

C2 - 29891605

AN - SCOPUS:85052024457

SN - 0066-4804

VL - 62

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 8

M1 - e01031-18

ER -

In vitro activity of ceftazidime-avibactam against carbapenem-resistant and hypervirulent klebsiella pneumoniae isolates

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this